Abstract
Tumor suppressor gene p16 is a cyclin-dependent kinase inhibitor and an important negative cell cycle regulator. The inactivation of p16 appears to be a common event in prostate cancer. Replacement of p16 inhibits prostate tumor cell growth, but the mechanism is not known. Human prostate cancer cell lines PPC-1, which has an inactivated p16, and DU145, which has a nonfunctional retinoblastoma Rb protein (pRb), were used to determine the possible mechanism of p16 mediated growth inhibition. PPC-1 cells treated with 5-aza-2′-deoxycytidine (5-aza-dC), a demethylating agent, induced p16 expression, inhibited cell growth, and induced senescence. Similarly, PPC-1 cells transduced by an adenoviral vector containing the p16 gene (AdRSVp16) produced a p16 protein that suppressed cellular proliferation and induced senescence. Co-staining of AdRSVp16-transduced PPC-1 cells by p16 immunohistochemistry and by β-galactosidase substrate X-gal showed that the morphologically enlarged cells expressed both p16 and senescence-associated β-galactosidase. In contrast, AdRSVp16 did not induce senescence in DU145 cells, but did inhibit its growth. However, when wild-type pRb was introduced in DU145 cells, AdRSVp16 was able to induce senescence. Thus, the mechanism by which p16 suppressed prostate cancer was dependent on the pRb functional status of cells whereby p16 caused pRb+ cells to undergo inhibition by senescence, whereas pRb− cells were also inhibited, but not by senescence.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Arap W, Nishikawa R, Furnari FB, Cavenee WK and Huang HJ . 1995 Cancer Res 55: 1351–1354
Bates S, Bonetta L, Macallan D, Parry D, Holder A, Dickson C and Peters G . 1994 Oncogene 9: 71–79
Banerjee A, Xu HJ, Hu SX, Araujo D, Takahashi R, Stanbridge EJ and Benedict WF . 1992 Cancer Res 52: 6297–6304
Bookstein R, Shew JY, Chen PL, Scully P and Lee WH . 1990 Science 24: 712–715
Cairns P, Polascik TJ, Eby Y and Sidransky D . 1995 Nature Genet 11: 210–212
Caldas C, Hahn SA, De Costa LT, Redston MS, Schutte M, Seymour AB, Weistein CL, Hruban RH, Yeo CJ and Kern SE . 1994 Nature Genet 8: 27–32
Chen Z-H, Zhang H and Savarese T . 1996 Cancer Res 56: 1083–1090
Craig C, Kim M, Ohri E, Wersto R, Katayose D, Li Z, Choi Y, Mudahar B, Srivastava S, Seth P and Cowan K . 1998 Oncogene 16: 265–272
Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I and Pereira-Smith O . 1995 Proc Natl Acad Sci USA 92: 9363–9367
Fairweather DS, Fox M and Margison GP . 1987 Exp Cell Res 168: 153–159
Foulkes WD, Flanders TY, Pollock PM and Hayward NK . 1997 Mol Med 3: 5–20
Fueyo J, Gomez-Manzano C, Yung WK, Clayman GL, Liu TJ, Bruner J, Levin VA and Kyritsis AP . 1996 Oncogene 12: 103–110
Geradts J and Wilson PA . 1996 Am J Path 149: 15–20
Gotoh A, Kao C, Ko S-C, Hamada K, Liu T-J and Chung LWK . 1997 J Urol 158: 636–641
Graham FL and Prevec L . 1991 Methods in Molecular Biology Murray EJ ed Human Press Inc, Chapter 11 pp 109–128
Guan KL, Jenkins CW, Li Y, Nichols MA, Wu X, O'keefe CL, Matera AG and Xiong Y . 1994 Genes Dev 8: 2923–2952
Haas K, Staller P, Geisen C, Bartek J, Eilers M and Moroy T . 1997 Oncogene 15: 179–192
Hama S, Sadatomo T, Yoshioka H, Kurisu K, Tahara E, Naruse I, Heike Y and Saijo N . 1997 Anticancer Res 17: 1933–1938
Hara E, Smith R, Parry D, Tahara H, Stone S and Peters G . 1996 Mol Cell Biol 16: 859–867
Hatta Y, Hirama T, Miller CW, Tomonaga M and Koeffler HP . 1995 Blood 85: 2699–2704
Herman JG, Jen J, Merlo A and Baylin SB . 1996 Cancer Res 56: 722–727
Holliday R . 1986 Exp Cell Res 166: 543–552
Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark WH, Tucker MA and Dracopoli NC . 1994 Nature Genet 8: 15–21
Itoh N, Kakehi Y, Akao T, Kinoshita H, Okada Y and Yoshida O . 1997 Jpn J Cancer Res 88: 229–233
Jarrard DF, Bova GS, Ewing CM, Pin SS, Nguyen SH, Baylin SB, Cairns P, Sidransky D, Herman JG and Isaacs WB . 1997 Genes Chromosomes Cancer 19: 90–96
Jarrard DF, Sarkar S, Shi Y, Yeager TR, Magrane G, Kinoshita H, Nassif N, Meisner L, Newton MA, Waldman FM and Reznikoff CA . 1999 Cancer Res 59: 2957–2964
Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JKV, Kinzler KW and Vogelstein B . 1994 Cancer Res 54: 6353–6358
Kratzke R, Otterson GA, Lincoln CE, Ewing S, Oie H, Geradts J and Kaye FJ . 1995 J Natl Cancer Inst 87: 1870–1875
Kratzke RA, Greatens JM, Rubins JB, Maddaus MA, Niewoehner DE, Niehans GA and Geradts J . 1996 Cancer Res 56: 3415–3420
Li YJ, Hoang-Xuan K, Delattre JY, Poisson M, Thomas G and Hamelin R . 1995 Oncogene 11: 597–600
Liggett WH and Sidransky D . 1998 J Clin Oncol 16: 1197–1206
Liu Q, Neuhausen S, Mcclure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, Allalunis-Turner MJ, Skolnick MH, Fujimura FK and Kamb A . 1995 Oncogene 10: 1061–1067
Loughran O, Malliri A, Owens D, Gallimore PH, Stanley MA, Ozanne B, Frame MC and Parkinson EK . 1996 Oncogene 13: 561–568
Lu Y, Whitaker L, Li X, Lotan D and Lotan R . 1995 Mol Cell Differ 3: 175–191
Lu Y, Zhang Y and Steiner MS . 1998a DNA Cell Biol 17: 643–645
Lu Y, Amos B, Cruise E, Lotan D and Lotan R . 1998b Biol Chem 379: 1323–1330
Lu Y, Carraher J, Zhang Y, Armstrong J, Lerner J, Roger W and Steiner MS . 1999 Cancer Gene Ther 6: 64–72
Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G and Bartek J . 1995 Nature 375: 503–506
Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ and Sidransky D . 1995 Cancer Res 55: 2995–2997
Mobley SR, Liu TJ, Hudson JM and Clayman GL . 1998 Arch Otolaryngol Head Neck Surg 124: 88–92
Mori T, Miura K, Aoki T, Nishihira T, Mori S and Nakamura Y . 1994 Cancer Res 54: 3396–3397
Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K and Carson DA . 1994 Nature 368: 753–756
Norbury C and Nurse P . 1992 Annu Rev Biochem 61: 441–470
Okamoto A, Demetrick DJ, Spillane EA, Hagiwara K, Hussain SP, Bennett WH, Forrester K, Gerwin B, Serrano M, Beach DH and Harris CC . 1994 Proc Natl Acad Sci USA 91: 11045–11049
Orlew I, Lacombe L, Hannon GJ, Serrano M, Pellicer I, Dalbagni G, Reuter VE, Zhang Z-F, Beach D and Cordon-Cardo C . 1995 J Intl Cancer Inst 87: 1524–1529
Palmero I, McConnell B, Parry D, Brookes S, Hara E, Bates S, Jat P and Peters G . 1997 Oncogene 15: 495–503
Park M and Koff A . 1998 Current Protocols in Cell Biology Bonifacino JS, Dasso M, Harford JB . Lippincott-Schwartz J and Yamada KM eds John Wiley & Sons, Inc Chapter 8 pp 831–8316
Quesnel B, Preudhomme C, Lepelley P, Hetuin D, Vanrumbeke M, Bauters F, Velu T and Fenaux P . 1996 Br J Hematol 95: 291–298
Reznikoff CA, Yeager TR, Belair CD, Savelieva E, Puthenveettil JA and Stadler WM . 1996 Cancer Res 56: 2886–2890
Sandig V, Brand K, Herwig S, Lukas J, Bartek J and Strauss M . 1997 Nature Med 3: 313–319
Sarkar FH, Sakr W, Li YW, et al. 1992 Prostate 21: 145–152
Schrump DS, Chen GA, Consuli U, Jin X and Roth JA . 1996 Cancer Gene Ther 3: 357–364
Serrano M, Hannon GJ and Beach D . 1993 Nature 366: 704–707
Serrano M, Gomez-Lahoz E, De Pinho RA, Beach D and Bar-Sagi D . 1995 Science 267: 249–252
Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D and Depinho RA . 1996 Cell 85: 27–37
Shapiro GI and Rollins BJ . 1996 Biochem Biophys Acta 1242: 165–169
Sherr CJ . 1993 Cell 73: 1059–1065
Smith-Sorenson B and Hovig E . 1995 Human Mutation 7: 294–303
Steiner MS and Anthony CT . 1996 Mol Cell Differ 4: 275–295
Steiner MS, Anthony CT, Lu Y and Holt JT . 1998 Human Gene Ther 9: 747–755
Steiner MS, Zhang Y, Farooq F, Lerner J, Wang Y and Lu Y . 1999a Cancer Gene Ther, in press
Steiner MS, Zhang Y, Carraher J and Lu Y . 1999b Cancer Gene Ther 6: 456–464
Stone S, Dayananth P and Kamb A . 1996 Cancer Res 56: 3199–3202
Takeuchi S, Bartram CR, Seriu T, Miller CW, Tobler A, Janssen JW, Reiter A, Ludwig WD, Zimmermann M, Schwaller J, et al . 1995 Blood 86: 755–760
Talve L, Sauroja I, Collan Y, Punnonen K and Ekfors T . 1997 Int J Cancer 74: 255–259
Uhrbom L, Nister M, Westermark B . 1997 Oncogene 15: 505–514
Vogt M, Haggblom C, Yeargin J, Christiansen-Weber T, Haas M . 1998 Cell Growth Differ 9: 139–146
Washimi O, Nagatake M, Osada H, Ueda R, Koshikawa T, Seki T, Takahashi T and Takahashi T . 1995 Cancer Res 55: 514–517
Wilson VL and Jones PA . 1983 Science 220: 1055–1057
Wolf JK, Kim TE, Fightmaster D, Bodurka D, Gershenson DM, Mills G and Wharton JT . 1999 Gynecol Oncol 73: 27–34
Xiao S, Li D, Vijg J, Sugarbaker DJ, Corson JM and Fletcher JA . 1995a Oncogene 11: 511–515
Xiao S, Li D, Corson JM, Vijg J and Fletcher JA . 1995b Cancer Res 55: 2968–2971
Zhang Y, Stein R, Wang W, Steiner MS and Lu Y . 1999a Tumor Targeting 4: 1–12
Zhang XW, Qing C and Xu B . 1999b Anticancer Drugs 10: 569–576
Acknowledgements
This research is supported in part by University of Tennessee Medical Group Morenton Oncology Research Grant and American Cancer Society Grant #IRG-87-008-09, and in part by Assisi Foundation of Memphis and J.R. Hyde, III Foundation. Adenoviral vector AdRSVp16 was kindly provided by Genotherapeutics, Inc.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Steiner, M., Wang, Y., Zhang, Y. et al. p16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways. Oncogene 19, 1297–1306 (2000). https://doi.org/10.1038/sj.onc.1203428
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203428
Keywords
This article is cited by
-
Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP
Oncogene (2016)
-
Radiation-induced cell death mechanisms
Tumor Biology (2010)
-
Regulation of cellular senescence by Rb2/p130
Oncogene (2006)
-
Cooperation between p53 and p130(Rb2) in induction of cellular senescence
Cell Death & Differentiation (2006)
-
Growth suppression by a p14ARF exon 1β adenovirus in human tumor cell lines of varying p53 and Rb status
Cancer Gene Therapy (2002)